This article is more than 5 years old. Information may no longer be current.

Shareholders approve proposals for Actavis’ planned acquisition of Forest

Actavis plc and Forest Inc. announced the approval of all proposals related to Actavis’ acquisition of Forest by its shareholders, according to a press release.

Actavis forecasts an annual revenue of about $15 billion in 2015 if the company successfully closes the transaction.

The approval of shareholders fulfills certain terms of the agreement, but closing of the transaction is subject to regulatory approvals and other closing conditions, which is expected to be completed by mid-year, the release said.

Actavis’ North American pharmaceuticals focus on women's health, urology, gastroenterology and dermatology categories, according to the release. Forest Inc. covers central nervous system, cardiovascular, gastrointestinal, respiratory, and anti-infective therapeutic areas.